top of page

NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis



NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).




14 views1 comment
bottom of page